<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02546609</url>
  </required_header>
  <id_info>
    <org_study_id>NS-0200-01</org_study_id>
    <nct_id>NCT02546609</nct_id>
  </id_info>
  <brief_title>The Effect Of NS-0200 Versus Placebo On Hepatic Fat Content In Patients With Non Alcoholic Fatty Liver Disease</brief_title>
  <official_title>A Randomized, Blinded, Placebo-Controlled Study To Evaluate The Effect Fixed-Dose Leucine, Metformin, Sildenafil Combinations(NS-0200) Versus Placebo On Hepatic Fat Assessed By MRI In Non Alcoholic Fatty Liver Disease Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NuSirt Biopharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NuSirt Biopharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to determine if NS-0200 can reduce the amount of liver fat in
      patients diagnosed with non-alcoholic fatty liver disease (NAFLD). This study will compare
      two doses of NS-0200 to placebo in NAFLD patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, 16-week, placebo-controlled, double-blind study to evaluate the effect
      of two fixed-dose combinations of leucine, metformin and sildenafil, NS-0200 compared to
      placebo, on the reduction of liver fat in patients diagnosed with non-alcoholic fatty liver
      disease (NAFLD). Subjects meeting all the inclusion criteria and no exclusion criteria will
      be randomized to one of three study arms.

      The primary objective of this study is to evaluate the change in hepatic fat content assessed
      by proton-density-fat-fraction (PDFF) employing magnetic resonance imaging (MRI) in subjects
      from : Screening/Visit 2 (Day-7/Week-1) to Study Termination/Visit 8 (Day 112/Week 16)
      receiving two fixed-dose combinations of leucine, metformin and sildenafil compared to
      placebo. Secondary objectives will also assess changes in serum alanine aminotransferase
      (ALT) activity, change in circulating cytokeratin 18, a surrogate marker of
      necro-inflammation, change in HbA1c, change in fasting glucose, insulin and insulin
      sensitivity, change in blood lipids such as cholesterol, LDL, HDL, triglycerides, and changes
      in in C-reactive protein. In addition this study will evaluate the safety and tolerability of
      NS-0200.

      Patients will have two screening visits, the first to determine their eligibility based on
      lab tests and the second based on the percentage of hepatic fat assessed by MRI imaging. Once
      qualified, patients will be randomly assigned to either one of the treatment groups or the
      placebo control group and monitored for a total of 16 weeks. Patients will return to the
      clinic each month for lab tests, and routine examinations. At the conclusion of the treatment
      period patients will again undergo an MRI scan to examine the percentage of hepatic fat.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 19, 2015</start_date>
  <completion_date type="Actual">January 31, 2017</completion_date>
  <primary_completion_date type="Actual">November 30, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Hepatic Fat</measure>
    <time_frame>Baseline, Day 112</time_frame>
    <description>To evaluate the change in hepatic fat content assessed by proton-density-fat-fraction (PDFF) employing magnetic resonance imaging (MRI).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Serum AlanineAaminotransferase (ALT) Levels</measure>
    <time_frame>Baseline, Day 112</time_frame>
    <description>Serum AlanineAminotransferase (ALT) will be examined through standard blood chemistry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Circulating Cytokeratin 18 Fragments (M30)</measure>
    <time_frame>Baseline, Day 112</time_frame>
    <description>Change in Circulating Cytokeratin 18 Fragments (M30) from Baseline to Week 16 will be examined through standard blood chemistry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Heamoglobin A1c (HbA1c)</measure>
    <time_frame>Baseline, Day 112</time_frame>
    <description>HbA1c will be examined through standard blood chemistry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fasting Glucose</measure>
    <time_frame>Baseline, Day 112</time_frame>
    <description>Fasting glucose will be examined through standard fasting blood chemistry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Insulin</measure>
    <time_frame>Baseline, Day 112</time_frame>
    <description>Insulin levels will be examined through standard blood chemistry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Blood Lipids (Cholesterol)</measure>
    <time_frame>Baseline, Day 112</time_frame>
    <description>Lipid levels such as cholesterol will be examined by standard blood chemistry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Blood Lipids (High Density Lipoprotein:HDL)</measure>
    <time_frame>Baseline, Day 112</time_frame>
    <description>Lipid levels such as HDL will be examined by standard blood chemistry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Low Density Lipoproteins (LDL)</measure>
    <time_frame>Baseline, Day 112</time_frame>
    <description>Lipid levels such as LDL will be examined by standard blood chemistry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Triglycerides</measure>
    <time_frame>Baseline, Day 112</time_frame>
    <description>Lipid levels such as triglycerides will be examined by standard blood chemistry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in C-reactive Protein</measure>
    <time_frame>Baseline, Day 112</time_frame>
    <description>CRP levels will be examined by standard blood chemistry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Insulin Sensitivity (HOMA-IR)</measure>
    <time_frame>Baseline, Day 112</time_frame>
    <description>HOMA-IR levels will be examined by standard blood chemistry</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">91</enrollment>
  <condition>NAFLD</condition>
  <arm_group>
    <arm_group_label>Leu Met Sil 0.5mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Leu-Met-Sil 0.5: 3 capsules BID consisting of 2 capsules containing 550 mg L-leucine each and 1 capsule containing 500 mg metformin and 0.5 mg of sildenafil.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Leu Met Sil 1.0mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Leu-Met-Sil 1.0: 3 capsules BID consisting of 2 capsules containing 550 mg L-leucine each and 1 capsule containing 500 mg metformin and 1.0 mg of sildenafil.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo: 3 capsules BID containing 99% Avicel PH302 and 1% magnesium stearate (w/w)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leu-Met-Sil 0.5</intervention_name>
    <description>NS-0200 low dose</description>
    <arm_group_label>Leu Met Sil 1.0mg</arm_group_label>
    <other_name>NS-0200-0.5</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leu-Met-Sil 1.0</intervention_name>
    <description>NS-200 high dose</description>
    <arm_group_label>Leu Met Sil 0.5mg</arm_group_label>
    <arm_group_label>Leu Met Sil 1.0mg</arm_group_label>
    <other_name>NS-0200-1.0</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Control arm</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18-75 at study entry.

          2. Is male, or female and, if female, meets all of the following criteria:

               1. Not breastfeeding

               2. Post-menopausal or negative serum pregnancy test result (human chorionic
                  gonadotropin, beta subunit [Î²-hCG]) at Screening /Visit 1 (Day-14/Week-2) (not
                  required for hysterectomized females)

               3. If of childbearing potential (including peri-menopausal women who have had a
                  menstrual period within one year) must practice and be willing to continue to
                  practice appropriate birth control (defined as a method which results in a low
                  failure rate, i.e., less than 1% per year, when used consistently and correctly,
                  such as double barrier methods [male condom with spermicide, with or without
                  cervical cap or diaphragm], implants, injectables, oral contraceptives [must have
                  been using for at least the last 3 months], some intrauterine contraceptive
                  devices, tubal ligation, or in an established relationship with a vasectomized
                  partner) during the entire duration of the study.

          3. Has been diagnosed with NAFLD via CT (positive for excess liver fat), ultrasound
             (positive for excess liver fat), MRI (PDFF showing &gt; 15% liver fat) or via biopsy
             (showing &gt;33% fat) within the past six months. If diagnosis was between 3 and 6 months
             prior to Screening, an ultrasound (positive for excess liver fat) is required prior to
             the Screening /Visit 1 (Day-14/Week-2) MRI.

          4. Has liver fat (as measured by PDFF via MRI) greater than 15% at Screening/Visit 2
             (Day-7/Week-1)

          5. Has had ALT levels &gt;30 U/L for men, &gt;19 U/L for women measured within 8 weeks of
             enrollment

          6. Has an HbA1c equal to or less than 9% at Screening /Visit 1 (Day-14/Week-2)

          7. Has a BMI between 25kg/m2 and 40 kg/m2

          8. Otherwise stable health for preceding twelve weeks

          9. Clinical laboratory tests (hematology, clinical chemistry, and urinalysis) either
             normal or with abnormalities consistent with NAFLD.

         10. Is able to read, understand, and sign the informed consent forms (ICF) and, when
             applicable, an authorization to use and disclose protected health information form
             (consistent with Health Insurance Portability and Accountability Act of 1996 [HIPAA]
             legislation), communicate with the investigator, and understand and comply with
             protocol requirements.

        Exclusion Criteria:

          1. Clinically significant renal dysfunction defined as a serum creatinine concentration
             &gt;1.4 mg/dL (females) or &gt;1.6 mg/dL (males) or a blood urea nitrogen concentration &gt;45
             mg/dL at screening.

          2. Use of any of the following medications:

               1. Metformin

               2. Combination drugs that include Metformin

               3. Sildenafil

               4. Tadalafil

               5. Vardenafil

               6. Pioglitazone

               7. Rosiglitazone

               8. Short acting insulins

               9. An alpha blocker

              10. Oral nitrates

              11. Medications associated with increased hepatic steatosis

              12. Insulins

              13. OCT2/MATE inhibitors (e.g. cimetidine, quinidine, and pyrimethamine)

                    -  Methotrexate

                    -  Tamoxifen

                    -  Corticosteroids (Nasal steroids are allowed if the subject has been on a
                       stable dose for the past 12 weeks and the dose employed does not exceed the
                       maximal recommended dose.)

                    -  Estrogens

                    -  Amiodarone

                    -  Valproic acid

                    -  Coumadin

                    -  Isoniazide

                    -  Nucleoside analogues used for the treatment of HIV infections

              14. Any dietary supplement other than multi-vitamins

          3. Evidence of significant alcohol consumption (defined as &gt;7 drinks/week for females and
             &gt;14 drinks/week for males) within 6 months prior to randomization or presence or
             suspicion of other forms of chronic liver disease (e.g., cirrhosis, autoimmune
             hepatitis (&gt;1:160 ANA), Wilson's disease, Hemochromatosis (Ferritin &gt;1000 ug/L and
             percent iron saturation &gt;45%), hepatitis A, B or C)

          4. Has a clinically significant medical condition that could potentially affect study
             participation and/or personal well-being, as judged by the investigator, including but
             not limited to the following conditions:

               1. Unable to undergo MRI or contraindications for MRI procedure

               2. History of cardio- or cerebro-vascular disease event within the previous 6 months

               3. Requires anti-coagulation therapy

               4. Gastrointestinal disorders including, but not limited to, the following:
                  pancreatitis, inflammatory bowel disease, or other diseases associated with
                  malabsorption or persistent abdominal discomfort

               5. Endocrine disorders other than type 2 diabetes and hypothyroidism on stable
                  replacement therapy

               6. Chronic infection (e.g., tuberculosis, human immunodeficiency virus infection,
                  hepatitis A virus, hepatitis B virus, or hepatitis C virus)

               7. Neurological or psychiatric diseases that preclude valid execution of informed
                  consent or may interfere with the subject's compliance with study procedures
                  (e.g., major depressive disorder within the last 2 years, a history of suicidal
                  behavior in the last 3 months)

               8. History of other psychiatric disorders including schizophrenia and bipolar
                  disorder)

          5. Participation in a weight loss program within the past 3 months.

          6. Weight change â¥5% during the past month.

          7. History of substance abuse (including alcohol abuse as defined above) in the past 3
             months or a positive screen for drugs of abuse or alcohol at screening.

          8. Has received any investigational drug within 3 months of Screening.

          9. Has donated blood within 3 months before Screening or is planning to donate blood
             during the study.

         10. Has had a serious infection, such as pneumonia in the previous 12 weeks

         11. Has known allergies or hypersensitivity to metformin, sildenafil or leucine

         12. Is an immediate family member (spouse, parent, child, or sibling; biological or
             legally adopted) of personnel directly affiliated with the study at the clinical study
             site, or NuSirt Biopharma.

         13. Is employed by NuSirt Biopharma (defined as an employee, temporary contract worker, or
             designee responsible for the conduct of the study).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Orville Kolterman, MD</last_name>
    <role>Study Director</role>
    <affiliation>NuSirt Biopharma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Catalina Research Institute</name>
      <address>
        <city>Chino</city>
        <state>California</state>
        <zip>91710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Research</name>
      <address>
        <city>Wheat Ridge</city>
        <state>Colorado</state>
        <zip>80033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta Gastroenterology Associates</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30312</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GI Specialists of Georgia</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sterling Research</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Premier Clinical Research</name>
      <address>
        <city>Clarksville</city>
        <state>Tennessee</state>
        <zip>37043</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastro One</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Quality Medical Research</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 3, 2015</study_first_submitted>
  <study_first_submitted_qc>September 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 11, 2015</study_first_posted>
  <results_first_submitted>February 26, 2018</results_first_submitted>
  <results_first_submitted_qc>April 3, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">May 2, 2018</results_first_posted>
  <last_update_submitted>April 3, 2018</last_update_submitted>
  <last_update_submitted_qc>April 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Sildenafil Citrate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects meeting all inclusion criteria and no exclusion criteria were randomized to one of the three treatment arms in the ratio of 1:1:1. Adult males and females (age 18-75) with CT, MRI, biopsy, or ultrasound consistent with NAFLD within the past 6 months.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>3 capsules BID containing 99% Avicel PH302 and 1% magnesium stearate (w/w)
Placebo: Placebo</description>
        </group>
        <group group_id="P2">
          <title>Leu Met Sil 0.5mg</title>
          <description>3 capsules BID consisting of 2 capsules containing 550 mg L-leucine each and 1 capsule containing 500 mg metformin and 0.5 mg of sildenafil.
Metformin: 500 mg Metformin BID
Leucine: 1100 mg Leucine BID
Sildenafil Citrate 0.5 mg: Sildenafil 0.5 mg BID</description>
        </group>
        <group group_id="P3">
          <title>Leu Met Sil 1.0mg</title>
          <description>3 capsules BID consisting of 2 capsules containing 550 mg L-leucine each and 1 capsule containing 500 mg metformin and 1.0 mg of sildenafil.
Sildenafil 1.0 mg: Sildenafil 1.0 mg
Metformin: 500 mg Metformin BID
Leucine: 1100 mg Leucine BID</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="35"/>
                <participants group_id="P3" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>travel or work schedule restriction</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Demographic and other baseline characteristics were analyzed using the ITT Population with subjects who met the inclusion criteria.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>3 capsules BID containing 99% Avicel PH302 and 1% magnesium stearate (w/w)
Placebo: Placebo</description>
        </group>
        <group group_id="B2">
          <title>Leu Met Sil 0.5mg</title>
          <description>3 capsules BID consisting of 2 capsules containing 550 mg L-leucine each and 1 capsule containing 500 mg metformin and 0.5 mg of sildenafil.
Metformin: 500 mg Metformin BID
Leucine: 1100 mg Leucine BID
Sildenafil Citrate 0.5 mg: Sildenafil 0.5 mg BID</description>
        </group>
        <group group_id="B3">
          <title>Leu Met Sil 1.0mg</title>
          <description>3 capsules BID consisting of 2 capsules containing 550 mg L-leucine each and 1 capsule containing 500 mg metformin and 1.0 mg of sildenafil.
Sildenafil 1.0 mg: Sildenafil 1.0 mg
Metformin: 500 mg Metformin BID
Leucine: 1100 mg Leucine BID</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
            <count group_id="B2" value="34"/>
            <count group_id="B3" value="32"/>
            <count group_id="B4" value="90"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="24"/>
                    <count group_id="B2" value="34"/>
                    <count group_id="B3" value="32"/>
                    <count group_id="B4" value="90"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="85"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="24"/>
                    <count group_id="B2" value="34"/>
                    <count group_id="B3" value="32"/>
                    <count group_id="B4" value="90"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.3" spread="10.42"/>
                    <measurement group_id="B2" value="45.1" spread="11.72"/>
                    <measurement group_id="B3" value="45.9" spread="12.71"/>
                    <measurement group_id="B4" value="45.7" spread="11.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="24"/>
                    <count group_id="B2" value="34"/>
                    <count group_id="B3" value="32"/>
                    <count group_id="B4" value="90"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="50"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="24"/>
                    <count group_id="B2" value="34"/>
                    <count group_id="B3" value="32"/>
                    <count group_id="B4" value="90"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="60"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="24"/>
                    <count group_id="B2" value="34"/>
                    <count group_id="B3" value="32"/>
                    <count group_id="B4" value="90"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="29"/>
                    <measurement group_id="B4" value="81"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="24"/>
                    <count group_id="B2" value="34"/>
                    <count group_id="B3" value="32"/>
                    <count group_id="B4" value="90"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="96.83" spread="15.061"/>
                    <measurement group_id="B2" value="94.44" spread="16.332"/>
                    <measurement group_id="B3" value="94.11" spread="17.225"/>
                    <measurement group_id="B4" value="94.96" spread="16.192"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="24"/>
                    <count group_id="B2" value="34"/>
                    <count group_id="B3" value="32"/>
                    <count group_id="B4" value="90"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="170.1" spread="9.48"/>
                    <measurement group_id="B2" value="169.6" spread="10.58"/>
                    <measurement group_id="B3" value="167" spread="10.75"/>
                    <measurement group_id="B4" value="168.8" spread="10.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body mass Index (BMI)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="24"/>
                    <count group_id="B2" value="34"/>
                    <count group_id="B3" value="32"/>
                    <count group_id="B4" value="90"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.5" spread="4.534"/>
                    <measurement group_id="B2" value="32.60" spread="3.486"/>
                    <measurement group_id="B3" value="33.52" spread="4.167"/>
                    <measurement group_id="B4" value="33.17" spread="4.008"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fasting Plasma Glucose</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="24"/>
                    <count group_id="B2" value="34"/>
                    <count group_id="B3" value="32"/>
                    <count group_id="B4" value="90"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="108.2" spread="16.53"/>
                    <measurement group_id="B2" value="104.3" spread="14.28"/>
                    <measurement group_id="B3" value="115.4" spread="27.61"/>
                    <measurement group_id="B4" value="109.3" spread="20.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HbA1c</title>
          <units>percentage of glycosylated hemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="24"/>
                    <count group_id="B2" value="34"/>
                    <count group_id="B3" value="32"/>
                    <count group_id="B4" value="90"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.59" spread="0.495"/>
                    <measurement group_id="B2" value="5.65" spread="0.528"/>
                    <measurement group_id="B3" value="5.86" spread="0.738"/>
                    <measurement group_id="B4" value="5.71" spread="0.609"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Childbearing Potential</title>
          <population>Childbearing potential is only applicable to the female participants hence the difference in overall population and number analyzed for this category.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                    <count group_id="B2" value="21"/>
                    <count group_id="B3" value="17"/>
                    <count group_id="B4" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Child-bearing potential with adequate birth contro</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Postmenopausal</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Surgically Sterile</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Hepatic Fat</title>
        <description>To evaluate the change in hepatic fat content assessed by proton-density-fat-fraction (PDFF) employing magnetic resonance imaging (MRI).</description>
        <time_frame>Baseline, Day 112</time_frame>
        <population>For the Per-Protocol Population (N=70), the mean percent change (SD) in hepatic fat content (%) from Baseline to Week 16 (Day 112) for each treatment group was assessed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>3 capsules BID containing 99% Avicel PH302 and 1% magnesium stearate (w/w)
Placebo: Placebo</description>
          </group>
          <group group_id="O2">
            <title>Leu Met Sil 0.5mg</title>
            <description>3 capsules BID consisting of 2 capsules containing 550 mg L-leucine each and 1 capsule containing 500 mg metformin and 0.5 mg of sildenafil.
Metformin: 500 mg Metformin BID
Leucine: 1100 mg Leucine BID
Sildenafil Citrate 0.5 mg: Sildenafil 0.5 mg BID</description>
          </group>
          <group group_id="O3">
            <title>Leu Met Sil 1.0mg</title>
            <description>3 capsules BID consisting of 2 capsules containing 550 mg L-leucine each and 1 capsule containing 500 mg metformin and 1.0 mg of sildenafil.
Sildenafil 1.0 mg: Sildenafil 1.0 mg
Metformin: 500 mg Metformin BID
Leucine: 1100 mg Leucine BID</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Hepatic Fat</title>
          <description>To evaluate the change in hepatic fat content assessed by proton-density-fat-fraction (PDFF) employing magnetic resonance imaging (MRI).</description>
          <population>For the Per-Protocol Population (N=70), the mean percent change (SD) in hepatic fat content (%) from Baseline to Week 16 (Day 112) for each treatment group was assessed.</population>
          <units>percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.046" spread="17.5335"/>
                    <measurement group_id="O2" value="3.083" spread="25.5230"/>
                    <measurement group_id="O3" value="-4.013" spread="24.6302"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis of variance (ANOVA) model: with treatment group as the factor. Placebo is used as the reference group.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0572</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Analysis of variance (ANOVA) model: with treatment group as the factor. Placebo is used as the reference group.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.3770</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Serum AlanineAaminotransferase (ALT) Levels</title>
        <description>Serum AlanineAminotransferase (ALT) will be examined through standard blood chemistry</description>
        <time_frame>Baseline, Day 112</time_frame>
        <population>For the Per-Protocol Population (N=70), the mean change (SD) in serum ALT levels from Baseline to Week 16 was assessed</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>3 capsules BID containing 99% Avicel PH302 and 1% magnesium stearate (w/w)
Placebo: Placebo</description>
          </group>
          <group group_id="O2">
            <title>Leu Met Sil 0.5mg</title>
            <description>3 capsules BID consisting of 2 capsules containing 550 mg L-leucine each and 1 capsule containing 500 mg metformin and 0.5 mg of sildenafil.
Metformin: 500 mg Metformin BID
Leucine: 1100 mg Leucine BID
Sildenafil Citrate 0.5 mg: Sildenafil 0.5 mg BID</description>
          </group>
          <group group_id="O3">
            <title>Leu Met Sil 1.0mg</title>
            <description>3 capsules BID consisting of 2 capsules containing 550 mg L-leucine each and 1 capsule containing 500 mg metformin and 1.0 mg of sildenafil.
Sildenafil 1.0 mg: Sildenafil 1.0 mg
Metformin: 500 mg Metformin BID
Leucine: 1100 mg Leucine BID</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum AlanineAaminotransferase (ALT) Levels</title>
          <description>Serum AlanineAminotransferase (ALT) will be examined through standard blood chemistry</description>
          <population>For the Per-Protocol Population (N=70), the mean change (SD) in serum ALT levels from Baseline to Week 16 was assessed</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.1" spread="20.09"/>
                    <measurement group_id="O2" value="1.8" spread="22.67"/>
                    <measurement group_id="O3" value="-2.7" spread="22.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>MMRM model: with treatment group, visit, and treatment-by-visit interaction as fixed effects, the baseline value of the response variable as a covariate, and subject as a random effect. Placebo is used as the reference group.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.3811</p_value>
            <method>Mixed Effect Model Repeat Measurement</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>MMRM model: with treatment group, visit, and treatment-by-visit interaction as fixed effects, the baseline value of the response variable as a covariate, and subject as a random effect. Placebo is used as the reference group.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.8479</p_value>
            <method>Mixed Effect Model Repeat Measurement</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Circulating Cytokeratin 18 Fragments (M30)</title>
        <description>Change in Circulating Cytokeratin 18 Fragments (M30) from Baseline to Week 16 will be examined through standard blood chemistry</description>
        <time_frame>Baseline, Day 112</time_frame>
        <population>For the Per-Protocol Population (N=70), the mean change (SD) in circulating cytokeratin 18 fragments (M30, U/L) from Baseline to week 16 was assessed</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>3 capsules BID containing 99% Avicel PH302 and 1% magnesium stearate (w/w)
Placebo: Placebo</description>
          </group>
          <group group_id="O2">
            <title>Leu Met Sil 0.5mg</title>
            <description>3 capsules BID consisting of 2 capsules containing 550 mg L-leucine each and 1 capsule containing 500 mg metformin and 0.5 mg of sildenafil.
Metformin: 500 mg Metformin BID
Leucine: 1100 mg Leucine BID
Sildenafil Citrate 0.5 mg: Sildenafil 0.5 mg BID</description>
          </group>
          <group group_id="O3">
            <title>Leu Met Sil 1.0mg</title>
            <description>3 capsules BID consisting of 2 capsules containing 550 mg L-leucine each and 1 capsule containing 500 mg metformin and 1.0 mg of sildenafil.
Sildenafil 1.0 mg: Sildenafil 1.0 mg
Metformin: 500 mg Metformin BID
Leucine: 1100 mg Leucine BID</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Circulating Cytokeratin 18 Fragments (M30)</title>
          <description>Change in Circulating Cytokeratin 18 Fragments (M30) from Baseline to Week 16 will be examined through standard blood chemistry</description>
          <population>For the Per-Protocol Population (N=70), the mean change (SD) in circulating cytokeratin 18 fragments (M30, U/L) from Baseline to week 16 was assessed</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.685" spread="306.3480"/>
                    <measurement group_id="O2" value="55.386" spread="273.1235"/>
                    <measurement group_id="O3" value="37.847" spread="222.6792"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>MMRM model: with treatment group, visit, and treatment-by-visit interaction as fixed effects, the baseline value of the response variable as a covariate, and subject as a random effect. Placebo is used as the reference group.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.7742</p_value>
            <method>Mixed effect Model Repeat Measurement</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>MMRM model: with treatment group, visit, and treatment-by-visit interaction as fixed effects, the baseline value of the response variable as a covariate, and subject as a random effect. Placebo is used as the reference group.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.6666</p_value>
            <method>Mixed effect Model Repeat Measurement</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Heamoglobin A1c (HbA1c)</title>
        <description>HbA1c will be examined through standard blood chemistry</description>
        <time_frame>Baseline, Day 112</time_frame>
        <population>For the Per-Protocol Population (N=70), the mean change (SD) in HbA1c from Baseline to Week 16 was assessed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>3 capsules BID containing 99% Avicel PH302 and 1% magnesium stearate (w/w)
Placebo: Placebo</description>
          </group>
          <group group_id="O2">
            <title>Leu Met Sil 0.5mg</title>
            <description>3 capsules BID consisting of 2 capsules containing 550 mg L-leucine each and 1 capsule containing 500 mg metformin and 0.5 mg of sildenafil.
Metformin: 500 mg Metformin BID
Leucine: 1100 mg Leucine BID
Sildenafil Citrate 0.5 mg: Sildenafil 0.5 mg BID</description>
          </group>
          <group group_id="O3">
            <title>Leu Met Sil 1.0mg</title>
            <description>3 capsules BID consisting of 2 capsules containing 550 mg L-leucine each and 1 capsule containing 500 mg metformin and 1.0 mg of sildenafil.
Sildenafil 1.0 mg: Sildenafil 1.0 mg
Metformin: 500 mg Metformin BID
Leucine: 1100 mg Leucine BID</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Heamoglobin A1c (HbA1c)</title>
          <description>HbA1c will be examined through standard blood chemistry</description>
          <population>For the Per-Protocol Population (N=70), the mean change (SD) in HbA1c from Baseline to Week 16 was assessed.</population>
          <units>percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07" spread="0.125"/>
                    <measurement group_id="O2" value="-0.15" spread="0.287"/>
                    <measurement group_id="O3" value="-0.11" spread="0.250"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>MMRM model: with treatment group, visit, and treatment-by-visit interaction as fixed effects, the baseline value of the response variable as a covariate, and subject as a random effect. Placebo is used as the reference group.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0020</p_value>
            <method>MMRM</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>MMRM model: with treatment group, visit, and treatment-by-visit interaction as fixed effects, the baseline value of the response variable as a covariate, and subject as a random effect. Placebo is used as the reference group.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0164</p_value>
            <method>MMRM</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Fasting Glucose</title>
        <description>Fasting glucose will be examined through standard fasting blood chemistry</description>
        <time_frame>Baseline, Day 112</time_frame>
        <population>For the Per-Protocol Population (N=70), the mean change (SD) in fasting glucose from Baseline to Week 16 was assessed. The difference in the actual participants analyzed and per protocol population is due to missing or technically erroneous data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>3 capsules BID containing 99% Avicel PH302 and 1% magnesium stearate (w/w)
Placebo: Placebo</description>
          </group>
          <group group_id="O2">
            <title>Leu Met Sil 0.5mg</title>
            <description>3 capsules BID consisting of 2 capsules containing 550 mg L-leucine each and 1 capsule containing 500 mg metformin and 0.5 mg of sildenafil.
Metformin: 500 mg Metformin BID
Leucine: 1100 mg Leucine BID
Sildenafil Citrate 0.5 mg: Sildenafil 0.5 mg BID</description>
          </group>
          <group group_id="O3">
            <title>Leu Met Sil 1.0mg</title>
            <description>3 capsules BID consisting of 2 capsules containing 550 mg L-leucine each and 1 capsule containing 500 mg metformin and 1.0 mg of sildenafil.
Sildenafil 1.0 mg: Sildenafil 1.0 mg
Metformin: 500 mg Metformin BID
Leucine: 1100 mg Leucine BID</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Fasting Glucose</title>
          <description>Fasting glucose will be examined through standard fasting blood chemistry</description>
          <population>For the Per-Protocol Population (N=70), the mean change (SD) in fasting glucose from Baseline to Week 16 was assessed. The difference in the actual participants analyzed and per protocol population is due to missing or technically erroneous data.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="10.66"/>
                    <measurement group_id="O2" value="-2.7" spread="11.59"/>
                    <measurement group_id="O3" value="-6.3" spread="9.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>MMRM model: with treatment group, visit, and treatment-by-visit interaction as fixed effects, the baseline value of the response variable as a covariate, and subject as a random effect. Placebo is used as the reference group.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.4099</p_value>
            <method>MMRM</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>MMRM model: with treatment group, visit, and treatment-by-visit interaction as fixed effects, the baseline value of the response variable as a covariate, and subject as a random effect. Placebo is used as the reference group.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.1455</p_value>
            <method>MMRM</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Insulin</title>
        <description>Insulin levels will be examined through standard blood chemistry</description>
        <time_frame>Baseline, Day 112</time_frame>
        <population>For the Per-Protocol Population (N=70), the mean change (SD) in insulin from Baseline to Week 16 was assessed. The difference in the actual participants analyzed and per protocol population is due to missing or technically erroneous data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>3 capsules BID containing 99% Avicel PH302 and 1% magnesium stearate (w/w)
Placebo: Placebo</description>
          </group>
          <group group_id="O2">
            <title>Leu Met Sil 0.5mg</title>
            <description>3 capsules BID consisting of 2 capsules containing 550 mg L-leucine each and 1 capsule containing 500 mg metformin and 0.5 mg of sildenafil.
Metformin: 500 mg Metformin BID
Leucine: 1100 mg Leucine BID
Sildenafil Citrate 0.5 mg: Sildenafil 0.5 mg BID</description>
          </group>
          <group group_id="O3">
            <title>Leu Met Sil 1.0mg</title>
            <description>3 capsules BID consisting of 2 capsules containing 550 mg L-leucine each and 1 capsule containing 500 mg metformin and 1.0 mg of sildenafil.
Sildenafil 1.0 mg: Sildenafil 1.0 mg
Metformin: 500 mg Metformin BID
Leucine: 1100 mg Leucine BID</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Insulin</title>
          <description>Insulin levels will be examined through standard blood chemistry</description>
          <population>For the Per-Protocol Population (N=70), the mean change (SD) in insulin from Baseline to Week 16 was assessed. The difference in the actual participants analyzed and per protocol population is due to missing or technically erroneous data.</population>
          <units>Î¼IU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.30" spread="24.38"/>
                    <measurement group_id="O2" value="-6.60" spread="12.30"/>
                    <measurement group_id="O3" value="-5.30" spread="15.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>MMRM model: with treatment group, visit, and treatment-by-visit interaction as fixed effects, the baseline value of the response variable as a covariate, and subject as a random effect. Placebo is used as the reference group.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.2559</p_value>
            <method>MMRM</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>MMRM model: with treatment group, visit, and treatment-by-visit interaction as fixed effects, the baseline value of the response variable as a covariate, and subject as a random effect. Placebo is used as the reference group.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.9776</p_value>
            <method>MMRM</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Blood Lipids (Cholesterol)</title>
        <description>Lipid levels such as cholesterol will be examined by standard blood chemistry</description>
        <time_frame>Baseline, Day 112</time_frame>
        <population>For the Per-Protocol Population (N=70), the mean change (SD) in total cholesterol from Baseline to Week 16 was assessed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>3 capsules BID containing 99% Avicel PH302 and 1% magnesium stearate (w/w)
Placebo: Placebo</description>
          </group>
          <group group_id="O2">
            <title>Leu Met Sil 0.5mg</title>
            <description>3 capsules BID consisting of 2 capsules containing 550 mg L-leucine each and 1 capsule containing 500 mg metformin and 0.5 mg of sildenafil.
Metformin: 500 mg Metformin BID
Leucine: 1100 mg Leucine BID
Sildenafil Citrate 0.5 mg: Sildenafil 0.5 mg BID</description>
          </group>
          <group group_id="O3">
            <title>Leu Met Sil 1.0mg</title>
            <description>3 capsules BID consisting of 2 capsules containing 550 mg L-leucine each and 1 capsule containing 500 mg metformin and 1.0 mg of sildenafil.
Sildenafil 1.0 mg: Sildenafil 1.0 mg
Metformin: 500 mg Metformin BID
Leucine: 1100 mg Leucine BID</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Blood Lipids (Cholesterol)</title>
          <description>Lipid levels such as cholesterol will be examined by standard blood chemistry</description>
          <population>For the Per-Protocol Population (N=70), the mean change (SD) in total cholesterol from Baseline to Week 16 was assessed.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="27.56"/>
                    <measurement group_id="O2" value="-20.5" spread="28.02"/>
                    <measurement group_id="O3" value="-5.9" spread="37.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>MMRM model: with treatment group, visit, and treatment-by-visit interaction as fixed effects, the baseline value of the response variable as a covariate, and subject as a random effect. Placebo is used as the reference group.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.2265</p_value>
            <method>MMRM</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>MMRM model: with treatment group, visit, and treatment-by-visit interaction as fixed effects, the baseline value of the response variable as a covariate, and subject as a random effect. Placebo is used as the reference group.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.8366</p_value>
            <method>MMRM</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Blood Lipids (High Density Lipoprotein:HDL)</title>
        <description>Lipid levels such as HDL will be examined by standard blood chemistry</description>
        <time_frame>Baseline, Day 112</time_frame>
        <population>For the Per-Protocol Population (N=70), the mean change (SD) in LDL from Baseline to Week 16 was assessed. The difference in the actual participants analyzed and per protocol population is because HDL could not be calculated for some participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>3 capsules BID containing 99% Avicel PH302 and 1% magnesium stearate (w/w)
Placebo: Placebo</description>
          </group>
          <group group_id="O2">
            <title>Leu Met Sil 0.5mg</title>
            <description>3 capsules BID consisting of 2 capsules containing 550 mg L-leucine each and 1 capsule containing 500 mg metformin and 0.5 mg of sildenafil.
Metformin: 500 mg Metformin BID
Leucine: 1100 mg Leucine BID
Sildenafil Citrate 0.5 mg: Sildenafil 0.5 mg BID</description>
          </group>
          <group group_id="O3">
            <title>Leu Met Sil 1.0mg</title>
            <description>3 capsules BID consisting of 2 capsules containing 550 mg L-leucine each and 1 capsule containing 500 mg metformin and 1.0 mg of sildenafil.
Sildenafil 1.0 mg: Sildenafil 1.0 mg
Metformin: 500 mg Metformin BID
Leucine: 1100 mg Leucine BID</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Blood Lipids (High Density Lipoprotein:HDL)</title>
          <description>Lipid levels such as HDL will be examined by standard blood chemistry</description>
          <population>For the Per-Protocol Population (N=70), the mean change (SD) in LDL from Baseline to Week 16 was assessed. The difference in the actual participants analyzed and per protocol population is because HDL could not be calculated for some participants.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" spread="23.81"/>
                    <measurement group_id="O2" value="-13.3" spread="27.16"/>
                    <measurement group_id="O3" value="1.2" spread="42.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>MMRM model: with treatment group, visit, and treatment-by-visit interaction as fixed effects, the baseline value of the response variable as a covariate, and subject as a random effect. Placebo is used as the reference group.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.3470</p_value>
            <method>MMRM</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>MMRM model: with treatment group, visit, and treatment-by-visit interaction as fixed effects, the baseline value of the response variable as a covariate, and subject as a random effect. Placebo is used as the reference group.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.6221</p_value>
            <method>MMRM</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Low Density Lipoproteins (LDL)</title>
        <description>Lipid levels such as LDL will be examined by standard blood chemistry</description>
        <time_frame>Baseline, Day 112</time_frame>
        <population>For the Per-Protocol Population (N=70), the mean change (SD) in LDL from Baseline to Week 16 was assessed. The difference in the actual participants analyzed and per protocol population is because LDL could not be calculated for some participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>3 capsules BID containing 99% Avicel PH302 and 1% magnesium stearate (w/w)
Placebo: Placebo</description>
          </group>
          <group group_id="O2">
            <title>Leu Met Sil 0.5mg</title>
            <description>3 capsules BID consisting of 2 capsules containing 550 mg L-leucine each and 1 capsule containing 500 mg metformin and 0.5 mg of sildenafil.
Metformin: 500 mg Metformin BID
Leucine: 1100 mg Leucine BID
Sildenafil Citrate 0.5 mg: Sildenafil 0.5 mg BID</description>
          </group>
          <group group_id="O3">
            <title>Leu Met Sil 1.0mg</title>
            <description>3 capsules BID consisting of 2 capsules containing 550 mg L-leucine each and 1 capsule containing 500 mg metformin and 1.0 mg of sildenafil.
Sildenafil 1.0 mg: Sildenafil 1.0 mg
Metformin: 500 mg Metformin BID
Leucine: 1100 mg Leucine BID</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Low Density Lipoproteins (LDL)</title>
          <description>Lipid levels such as LDL will be examined by standard blood chemistry</description>
          <population>For the Per-Protocol Population (N=70), the mean change (SD) in LDL from Baseline to Week 16 was assessed. The difference in the actual participants analyzed and per protocol population is because LDL could not be calculated for some participants.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" spread="23.81"/>
                    <measurement group_id="O2" value="-13.3" spread="27.16"/>
                    <measurement group_id="O3" value="1.2" spread="42.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>MMRM model: with treatment group, visit, and treatment-by-visit interaction as fixed effects, the baseline value of the response variable as a covariate, and subject as a random effect. Placebo is used as the reference group.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.3470</p_value>
            <method>MMRM</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>MMRM model: with treatment group, visit, and treatment-by-visit interaction as fixed effects, the baseline value of the response variable as a covariate, and subject as a random effect. Placebo is used as the reference group.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.6221</p_value>
            <method>MMRM</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Triglycerides</title>
        <description>Lipid levels such as triglycerides will be examined by standard blood chemistry</description>
        <time_frame>Baseline, Day 112</time_frame>
        <population>Geometric mean values are presented since the data were skewed. Corresponding arithmetic mean changes from baseline for Treatments A, B and C in the Per Protocol Population were +54.9, -48.9 and -28.0 mg/dL respectively. This accounts for the p-value of p=0.0129 for Treatment B.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>3 capsules BID containing 99% Avicel PH302 and 1% magnesium stearate (w/w)
Placebo: Placebo</description>
          </group>
          <group group_id="O2">
            <title>Leu Met Sil 0.5mg</title>
            <description>3 capsules BID consisting of 2 capsules containing 550 mg L-leucine each and 1 capsule containing 500 mg metformin and 0.5 mg of sildenafil.
Metformin: 500 mg Metformin BID
Leucine: 1100 mg Leucine BID
Sildenafil Citrate 0.5 mg: Sildenafil 0.5 mg BID</description>
          </group>
          <group group_id="O3">
            <title>Leu Met Sil 1.0mg</title>
            <description>3 capsules BID consisting of 2 capsules containing 550 mg L-leucine each and 1 capsule containing 500 mg metformin and 1.0 mg of sildenafil.
Sildenafil 1.0 mg: Sildenafil 1.0 mg
Metformin: 500 mg Metformin BID
Leucine: 1100 mg Leucine BID</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Triglycerides</title>
          <description>Lipid levels such as triglycerides will be examined by standard blood chemistry</description>
          <population>Geometric mean values are presented since the data were skewed. Corresponding arithmetic mean changes from baseline for Treatments A, B and C in the Per Protocol Population were +54.9, -48.9 and -28.0 mg/dL respectively. This accounts for the p-value of p=0.0129 for Treatment B.</population>
          <units>mg/dL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="0.06"/>
                    <measurement group_id="O2" value="0.8" spread="0.06"/>
                    <measurement group_id="O3" value="0.9" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>MMRM model: with treatment group, visit, and treatment-by-visit interaction as fixed effects, the baseline value of the response variable as a covariate, and subject as a random effect. Placebo is used as the reference group.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0129</p_value>
            <method>MMRM</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>MMRM model: with treatment group, visit, and treatment-by-visit interaction as fixed effects, the baseline value of the response variable as a covariate, and subject as a random effect. Placebo is used as the reference group.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.4316</p_value>
            <method>MMRM</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in C-reactive Protein</title>
        <description>CRP levels will be examined by standard blood chemistry</description>
        <time_frame>Baseline, Day 112</time_frame>
        <population>For the Per-Protocol Population (N=70), the geometric mean change (SE) in C-reactive protein from Baseline to Week 16 was assessed. The difference in the actual participants analyzed and per protocol population is due to missing or technically erroneous data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>3 capsules BID containing 99% Avicel PH302 and 1% magnesium stearate (w/w)
Placebo: Placebo</description>
          </group>
          <group group_id="O2">
            <title>Leu Met Sil 0.5mg</title>
            <description>3 capsules BID consisting of 2 capsules containing 550 mg L-leucine each and 1 capsule containing 500 mg metformin and 0.5 mg of sildenafil.
Metformin: 500 mg Metformin BID
Leucine: 1100 mg Leucine BID
Sildenafil Citrate 0.5 mg: Sildenafil 0.5 mg BID</description>
          </group>
          <group group_id="O3">
            <title>Leu Met Sil 1.0mg</title>
            <description>3 capsules BID consisting of 2 capsules containing 550 mg L-leucine each and 1 capsule containing 500 mg metformin and 1.0 mg of sildenafil.
Sildenafil 1.0 mg: Sildenafil 1.0 mg
Metformin: 500 mg Metformin BID
Leucine: 1100 mg Leucine BID</description>
          </group>
        </group_list>
        <measure>
          <title>Change in C-reactive Protein</title>
          <description>CRP levels will be examined by standard blood chemistry</description>
          <population>For the Per-Protocol Population (N=70), the geometric mean change (SE) in C-reactive protein from Baseline to Week 16 was assessed. The difference in the actual participants analyzed and per protocol population is due to missing or technically erroneous data.</population>
          <units>mg/L</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.02" spread="0.129"/>
                    <measurement group_id="O2" value="1.27" spread="0.178"/>
                    <measurement group_id="O3" value="1.08" spread="0.170"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>MMRM model: with treatment group, visit, and treatment-by-visit interaction as fixed effects, the baseline value of the response variable as a covariate, and subject as a random effect. Placebo is used as the reference group.</non_inferiority_desc>
            <p_value>0.1946</p_value>
            <method>MMRM</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>MMRM model: with treatment group, visit, and treatment-by-visit interaction as fixed effects, the baseline value of the response variable as a covariate, and subject as a random effect. Placebo is used as the reference group.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.4697</p_value>
            <method>MMRM</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Insulin Sensitivity (HOMA-IR)</title>
        <description>HOMA-IR levels will be examined by standard blood chemistry</description>
        <time_frame>Baseline, Day 112</time_frame>
        <population>For the Per-Protocol Population (N=70), the change in geometric mean (SE) in HOMA-IR from Baseline to Week 16 was assessed. The difference in the actual participants analyzed and per protocol population is due to missing or technically erroneous data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>3 capsules BID containing 99% Avicel PH302 and 1% magnesium stearate (w/w)
Placebo: Placebo</description>
          </group>
          <group group_id="O2">
            <title>Leu Met Sil 0.5mg</title>
            <description>3 capsules BID consisting of 2 capsules containing 550 mg L-leucine each and 1 capsule containing 500 mg metformin and 0.5 mg of sildenafil.
Metformin: 500 mg Metformin BID
Leucine: 1100 mg Leucine BID
Sildenafil Citrate 0.5 mg: Sildenafil 0.5 mg BID</description>
          </group>
          <group group_id="O3">
            <title>Leu Met Sil 1.0mg</title>
            <description>3 capsules BID consisting of 2 capsules containing 550 mg L-leucine each and 1 capsule containing 500 mg metformin and 1.0 mg of sildenafil.
Sildenafil 1.0 mg: Sildenafil 1.0 mg
Metformin: 500 mg Metformin BID
Leucine: 1100 mg Leucine BID</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Insulin Sensitivity (HOMA-IR)</title>
          <description>HOMA-IR levels will be examined by standard blood chemistry</description>
          <population>For the Per-Protocol Population (N=70), the change in geometric mean (SE) in HOMA-IR from Baseline to Week 16 was assessed. The difference in the actual participants analyzed and per protocol population is due to missing or technically erroneous data.</population>
          <units>mU/L</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.89" spread="0.076"/>
                    <measurement group_id="O2" value="0.80" spread="0.078"/>
                    <measurement group_id="O3" value="0.85" spread="0.096"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>MMRM model: with treatment group, visit, and treatment-by-visit interaction as fixed effects, the baseline value of the response variable as a covariate, and subject as a random effect. Placebo is used as the reference group.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.3474</p_value>
            <method>MMRM</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>MMRM model: with treatment group, visit, and treatment-by-visit interaction as fixed effects, the baseline value of the response variable as a covariate, and subject as a random effect. Placebo is used as the reference group.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.8832</p_value>
            <method>MMRM</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>112 days</time_frame>
      <desc>Treatment-Emergent Adverse Event (TEAE) is defined as an adverse event occurring on or after the first dose of randomized study medication, or existing prior to the time of and worsening after the time of the first dose of randomized study medication.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>3 capsules BID containing 99% Avicel PH302 and 1% magnesium stearate (w/w)
Placebo: Placebo</description>
        </group>
        <group group_id="E2">
          <title>Leu Met Sil 0.5mg</title>
          <description>3 capsules BID consisting of 2 capsules containing 550 mg L-leucine each and 1 capsule containing 500 mg metformin and 0.5 mg of sildenafil.
Metformin: 500 mg Metformin BID
Leucine: 1100 mg Leucine BID
Sildenafil Citrate 0.5 mg: Sildenafil 0.5 mg BID</description>
        </group>
        <group group_id="E3">
          <title>Leu Met Sil 1.0mg</title>
          <description>3 capsules BID consisting of 2 capsules containing 550 mg L-leucine each and 1 capsule containing 500 mg metformin and 1.0 mg of sildenafil.
Sildenafil 1.0 mg: Sildenafil 1.0 mg
Metformin: 500 mg Metformin BID
Leucine: 1100 mg Leucine BID</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Gastritis erosive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Type 2 Diabetes mellitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision Blurred</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="34"/>
                <counts group_id="E3" events="12" subjects_affected="12" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="24"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="34"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="34"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="34"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Blood triglycerides increase</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis Contact</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Barbara Cannon</name_or_title>
      <organization>Nusirt Biopharma Inc.</organization>
      <phone>615-656-7898</phone>
      <email>BCannon@nusirt.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

